Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SANGUINE CORP. (SGNC) -- Ignore unavailable to you. Want to Upgrade?

To: Profiteer who wrote (3744)	8/16/1998 2:04:00 PM
From: Jim B	Read Replies (1) \| Respond to of 5402

yep.. that's cool.. the story of this one will unfold in a matter of months.. it won't end for a few years... but again.. won't be long before we have reason to consider further adding to positions or jumping in off the sidelines. just have to wait for more news. jim

To: Profiteer who wrote (3744)	8/16/1998 2:07:00 PM
From: Profiteer	Respond to of 5402

Hemoglobin-bases Substitute (Still not the answer!) Chicago(Reuters) Researchers for decades have pursued a synthetic blood substitute, seeking a product that can be stored longer, filtered cleaner and used more quickly than donated whole blood because it would not have to be typed and cross-matched. Hope was running high for a breakthrough a few years ago as the biotechnology revolution swept through the blood substitute field, but companies one-by-one have encountered snags. Most recently, Baxter International Inc. , of Deerfield, Ill., in July shut down trials with its blood substitute, which is molecularly different from PolyHeme. Both products are derived from hemoglobin in unused donor blood. ''There's a lot more research and issues that need to be overcome before we see an approvable hemoglobin-based oxygen carrier,'' said John Wong, head of the biotechnology consulting firm SciFin Inc. in Los Angeles. ^REUTERS@ Reut16:14 08-12-98